Thus, the results show that the EGF+61 A>G polymorphism does not influence disease outcomes, both PFS and OS from NSCLC TKI‐treated patients harboring EGFR‐sensitizing mutations. The gene discussed is EGF; the disease is non-small cell lung carcinoma.